We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreWhen making a decision about the approval of a new product NICE (National Institute for Health and C...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe use of combination therapy is increasingly becoming the standard of care in oncology as cancers ...
Read moreThe QALY Shortfall aims to capture and recognise disease severity by assessing the degree of quality...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreInsights from pharmaceuticals, market access and Team Remap Q3 2021.
Read moreThe introduction of new medicines in England requires the cooperation of industry and the NHS.
Read moreNICE is increasing opportunities for patient engagement by simplifying the process and increasing pa...
Read moreNICE’s remodel plans focus on delivering faster and fairer access to treatments by optimising appr...
Read more